#term loan

Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, entered into the second amendment to its loan and security agreement (LSA) with Oxford Finance, pursuant to which the lenders

Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, amended its existing credit agreement with funds managed by GoldenTree Asset Management and other existing lender

Dyne Therapeutics, a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, entered into an amendment to its non-dilutive senior secured term loan facility with Hercules C